NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc....

REGN announces business updates at the J.P. Morgan Healthcare Conference.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pu...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 5:15 PM ET Company Participants Leonard Schleifer - Board Co-Chair, Co-Founder, Presi...

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.

Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the w...

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Regeneron business and prospects, resulting in its stock trading at inflated prices.

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Regeneron business and prospects, resulting in its stock trading at inflated prices.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Regeneron Pharmaceuticals, Inc. (“Regeneron” or...

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

LOS ANGELES--(BUSINESS WIRE)--REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captione...

Regeneron Pharmaceuticals continues to show strong growth, driven by Dupixent's FDA approval for COPD and Eylea HD's market resilience against biosimilars. Q3 earnings beat expectations with $3.72 bil...

Biotech giant Regeneron Pharmaceuticals (REGN 1.08%) started 2024 on a strong note and performed well through the first half of the year. However, the drugmaker has since seen its shares decline subst...

Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.

REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.

Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and D...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relati...